Table 1. Overall expression of class I HDAC isoforms in prostate carcinoma as well as distribution of class I HDAC isoform expression in the study population stratified for selected tumour parameters.
| Total | HDAC1 low | HDAC1 high | P-value | HDAC2 low | HDAC2 high | P-value | HDAC3 low | HDAC3 high | P-value | |
|---|---|---|---|---|---|---|---|---|---|---|
| All cases | 192 (100%) | 58 (30.2%) | 134 (69.8%) | 50 (26%) | 142 (74%) | 10 (5.2%) | 182 (94.8%) | |||
| PSA ⩽10 ng ml−1 | 75 (48.1%) | 23 (30.7%) | 52 (69.3%) | 0.610+ | 23 (30.7%) | 52 (69.3%) | 0.474+ | 4 (5.3%) | 71 (94.7%) | 1.000+ |
| PSA >10 ng ml−1 | 81 (51.9%) | 29 (35.8%) | 52 (64.2%) | 20 (24.7%) | 61 (75.3%) | 5 (6.2%) | 76 (93.8%) | |||
| Age ⩽65 | 134 (69.8%) | 43 (32.1%) | 91 (67.9%) | 0.494+ | 29 (21.6%) | 105 (78.4%) | 0.048+ | 8 (6%) | 126 (94%) | 0.726+ |
| Age >65 | 58 (30.2%) | 15 (25.9%) | 43 (74.1%) | 21 (36.2%) | 37 (63.8%) | 2 (3.4%) | 56 (96.6%) | |||
| pT2 | 97 (50.5%) | 32 (33%) | 65 (67%) | 0.580* | 28 (28.9%) | 69 (71.1%) | 0.398* | 5 (5.2%) | 92 (94.8%) | 0.925* |
| pT3 | 91 (47.4%) | 24 (26.4%) | 67 (73.6%) | 21 (23.1%) | 70 (76.9%) | 5 (5.5%) | 86 (94.5%) | |||
| pT4 | 4 (2.1%) | 2 (50%) | 2 (50%) | 1 (25%) | 3 (75%) | 0 (0%) | 4 (100%) | |||
| Gleason sum 2–6 | 70 (36.5%) | 31 (44.3%) | 39 (55.7%) | 0.006* | 24 (34.3%) | 46 (65.7%) | 0.047* | 5 (7.1%) | 65 (92.9%) | 0.584* |
| Gleason sum 7 | 64 (33.3%) | 14 (21.9%) | 50 (78.1%) | 15 (23.4%) | 49 (76.6%) | 2 (3.1%) | 62 (96.9%) | |||
| Gleason sum 8–10 | 58 (30.2%) | 13 (22.4%) | 45 (77.6%) | 11 (19%) | 47 (81%) | 3 (5.2%) | 55 (94.8%) | |||
| R0 | 100 (52.1%) | 29 (29%) | 71 (71%) | 0.754+ | 30 (30%) | 70 (70%) | 0.249+ | 5 (5%) | 95 (95%) | 1.000+ |
| R1 | 92 (47.9%) | 29 (31.5%) | 63 (68.5%) | 20 (21.7%) | 72 (78.3%) | 5 (5.4%) | 87 (94.6%) | |||
| HDAC1 low | 58 (30.2%) | — | — | — | 23 (39.7%) | 35 (60.3%) | 0.007+ | 10 (17.2%) | 48 (82.8%) | <0.001+ |
| HDAC1 high | 134 (69.8%) | — | — | 27 (20.1%) | 107 (79.9%) | 0 (0%) | 134 (100%) | |||
| HDAC2 low | 50 (26%) | 23 (46%) | 27 (54%) | 0.007+ | — | — | — | 7 (14%) | 43 (86%) | 0.004+ |
| HDAC2 high | 142 (74%) | 35 (24.6%) | 107 (75.4%) | — | — | 3 (2.1%) | 139 (97.9%) | |||
| HDAC3 low | 10 (5.2%) | 10 (100%) | 0 (0%) | <0.001+ | 7 (70%) | 3 (30%) | 0.004+ | — | — | — |
| HDAC3 high | 182 (94.8%) | 48 (26.4%) | 134 (73.6%) | 43 (23.6%) | 139 (76.4%) | — | — | |||
| Ki-67 index mean | 8.60 | 6.88 | 9.30 | 0.032# | 6.44 | 9.30 | 0.002# | 4.00 | 8.83 | <0.001# |
| Ki-67 index s.d. | 6.62 | 0.82 | 0.63 | 0.61 | 0.64 | 0.63 | 0.53 | |||
| DFS probability median | 0.70 | 0.80 | 0.60 | 0.203$ | 0.83 | 0.60 | 0.036$ | 0.60 | 0.70 | 0.946$ |
| DFS probability quart. | 0.3–0.9 | 0.30–0.91 | 0.30–0.86 | 0.40–0.93 | 0.30–0.85 | 0.20–0.90 | 0.30–0.90 |
DFS=disease-free survival; HDAC=histone deacetylase.
In the first row overall distribution of the respective tumour parameters in the study population is listed.
+Fisher's exact test, *χ2-test for trends, #unpaired t-test $, Mann–Whitney U-test.